Colorectal cancer screening: Assessment of CEACAM6, LGALS4, TSPAN8 and COL1A2 as blood markers in faecal immunochemical test negative subjects

Enea Ferlizza, Rossella Solmi, Rossella Miglio, Elena Nardi, Gabriella Mattei, Michela Sgarzi, Mattia Lauriola, Enea Ferlizza, Rossella Solmi, Rossella Miglio, Elena Nardi, Gabriella Mattei, Michela Sgarzi, Mattia Lauriola

Abstract

Prevention is essential to reduce Colorectal Cancer (CRC) mortality. We previously reported a panel of four genes: CEACAM6, LGALS4, TSPAN8, COL1A2 (CELTiC) able to discriminate patients with CRC. Here, we assessed the CELTiC panel by quantitative polymerase chain reaction, in the blood of 174 healthy subjects, who resulted negative to the faecal immunochemical test (FITN). Using non-parametric statistic and multinomial logistic models, the FITN were compared to previously analysed subjects: 36 false positive FIT (NFIT), who were negative at colonoscopy, 36 patients with low risk lesions (LR) and 92 patients with high risk lesions or CRC (HR/CRC). FITN showed a significantly lower expression of the four genes when compared to HR/CRC. Moreover, FITN showed a significantly lower expression of TSPAN8 and COL1A2 compared to NFIT and LR patients. The multinomial logistic model confirmed that TSPAN8 alone specifically discriminated FITN from NFIT, LR and HR/CRC, while LGALS4 was able to differentiate FITN from false positive FIT. Finally, ROC curves analysis of the comparisons between FITN and HR/CRC, LR or NFIT reported AUC greater than 0.87, with a sensitivity and specificity of 83% and 76%, respectively. The CELTiC panel was confirmed a useful tool to identify CRC patients and to discriminate false FIT positive subjects.

Keywords: Blood mRNA; CEACAM6; COL1A2; Faecal immunochemical test; LGALS4; TSPAN8.

© 2020 THE AUTHORS. Published by Elsevier BV on behalf of Cairo University.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Graphical representation of the technical variability assay. Three samples were selected. Each sample was divided into 10 aliquots (replicates). For each sample, four aliquots (replicates) were extracted in one day to calculate within-assay variability. The other six aliquots were extracted on two different days (three replicates per day). After extraction of all the replicates of each sample, total RNA was reverse-transcribed and cDNA amplified on different days.
Fig. 2
Fig. 2
Enrollment and outcomes. Study plan describing admission of 174 subjects with negative fecal immunochemical test (FITN). The distribution of cases of 164 samples collected in our previous studies , is also reported.
Fig. 3
Fig. 3
Box-plot of the quantification cycles (ΔCq), normalised on the housekeeping gene, of the CELTiC markers for the four groups analysed. CEACAM6, carcinoembryonic antigen-related cell-adhesion molecule 6; LGALS4, lectin galactoside-binding soluble 4; TSPAN8, tetraspanin 8; COL1A2, collagen type I alpha 2 chain. FITN, healthy FIT negative; NFIT, negative-colonoscopy FIT-positive; LR, low risk; HR/CRC, high risk/colorectal cancer. * indicate significant difference between groups (p < 0.05).
Fig. 4
Fig. 4
ROC curves of the CELTiC panel for the comparisons of FITN vs the other groups. AUC, area under curve; Se, sensitivity; Sp, specificity; FITN, healthy FIT negative; NFIT, negative-colonoscopy FIT-positive; LR, low risk; HR/CRC, high risk/colorectal cancer.

References

    1. Hadjipetrou A., Anyfantakis D., Galanakis C.G., Kastanakis M., Kastanakis S. Colorectal cancer, screening and primary care: a mini literature review. World J Gastroenterol. 2017;23(133):6049–6058.
    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
    1. Senore C., Basu P., Anttila A., Ponti A., Tomatis M., Vale D.B. Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. Int J Cancer. 2018;142:44–56.
    1. Benson V.S., Atkin W.S., Green J., Nadel M.R., Patnick J., Smith R.A. Toward standardizing and reporting colorectal cancer screening indicators on an international level: the international colorectal cancer screening network. Int J Cancer. 2012;130:2961–2973.
    1. Venturelli F., Sampaolo L., Carrozzi G., Zappa M., Giorgi Rossi P., Rossi P.G. Associations between cervical, breast and colorectal cancer screening uptake, chronic diseases and health-related behaviours: Data from the Italian PASSI nationwide surveillance. Prev Med. 2019;120:60–70.
    1. Zorzi M., Hassan C., Capodaglio G., Fedato C., Montaguti A., Turrin A. Long-term performance of colorectal cancer screening programmes based on the faecal immunochemical test. Gut. 2018;67:2124–2130.
    1. Schreuders E.H., Ruco A., Rabeneck L., Schoen R.E., Sung J.J.Y., Young G.P. Colorectal cancer screening: A global overview of existing programmes. Gut. 2015;64:1637–1649.
    1. Idigoras Rubio I., Arana-Arri E., Portillo Villares I., Bilbao Iturribarrria I., Martinez-Indart L., Imaz-Ayo N. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years. Eur J Gastroenterol Hepatol. 2019;31:197–204.
    1. Rosso C., Cabianca L., Gili F.M. Non-invasive markers to detect colorectal cancer in asymptomatic population. Minerva Biotecnol. 2019;31(1):23–29.
    1. Botteri E., Crosta C., Bagnardi V., Tamayo D., Sonzogni A.M., De Roberto G. Predictors of advanced colorectal neoplasia at initial and surveillance colonoscopy after positive screening immunochemical faecal occult blood test. Dig Liver Dis. 2016;48:321–326.
    1. Tao S., Seiler C.M., Ronellenfitsch U., Brenner H. Comparative evaluation of nine faecal immunochemical tests for the detection of colorectal cancer. Acta Oncol. 2013;52:1667–1675.
    1. Normanno N., Cervantes A., Ciardiello F., De Luca A, De Luca A., Pinto C. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat Rev. 2018;70:1–8.
    1. Rodia M.T., Ugolini G., Mattei G., Montroni I., Zattoni D., Ghignone F. Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget. 2016;7:30295–30306.
    1. Gemei M., Mirabelli P., Di Noto R., Corbo C., Iaccarino A., Zamboli A. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo. Cancer. 2013;119(4):729–738.
    1. Kuroki M., Matsushita H., Matsumoto H., Hirose Y., Senba T., Yamamoto T. Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marke. Anticancer Res. 1999;19:5599–5606.
    1. Cao Z.Q., Guo X.L. The role of galectin-4 in physiology and diseases. Protein Cell. 2016;7(5):314–324.
    1. Makoto W., Ichiro T., Naoki K., Yuhki Y., Matsuo E.I., Susumu I. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep. 2011;25(5):1217–1226.
    1. Richardson M.M., Jennings L.K., Zhang X.A. Tetraspanins and tumor progression. Clin Exp Metastasis. 2011;28(3):261–270.
    1. Nazarenko I., Rana S., Baumann A., McAlear J., Hellwig A., Trendelenburg M. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010;70(4):1668–1678.
    1. Greco C., Bralet M.P., Ailane N., Dubart-Kupperschmitt A., Rubinstein E., Le Naour F. E-cadherin/p120-catenin and tetraspanin Co-029 cooperate for cell motility control in human colon carcinoma. Cancer Res. 2010;70(19):7674–7683.
    1. Rodia M.T., Solmi R., Pasini F., Nardi E., Mattei G., Ugolini G. LGALS4, CEACAM6, TSPAN8, and COL1A2: blood markers for colorectal cancer—validation in a cohort of subjects with positive fecal immunochemical test result. Clin Colorectal Cancer. 2018;17(2):e217–e228.
    1. Hamm A., Prenen H., Van Delm W, Di Matteo M, Wenes M., Delamarre E. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut. 2016;65:990–1000.
    1. Broeders S., Huber I., Grohmann L., Berben G., Taverniers I., Mazzara M. Guidelines for validation of qualitative real-time PCR methods. Trends Food Sci Technol. 2014;37:115–126.
    1. Mattocks C.J., Morris M.A., Matthijs G., Swinnen E., Corveleyn A., Dequeker E. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet. 2010;18:1276–1288.
    1. Ganepola G.A., Nizin J., Rutledge J.R., Chang D.H. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. World J Gastrointest Oncol. 2014;6:83–97.
    1. Yamada T., Matsuda A., Koizumi M., Shinji S., Takahashi G., Iwai T. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019;99:39–45.
    1. Yörüker E.E., Holdenrieder S., Gezer U. Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer. Clin Chim Acta. 2016;455:26–32.
    1. Navarro M., Nicolas A., Ferrandez A., Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J Gastroenterol. 2017;23(20):3632.
    1. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29
    1. Kralik P., Ricchi M. A basic guide to real time PCR in microbial diagnostics: Definitions, parameters, and everything. Front Microbiol. 2017;8:1–9.
    1. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–622.
    1. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–1108.
    1. Byron S.A., Van Keuren-Jensen K.R., Engelthaler D.M., Carpten J.D., Craig D.W. Translating RNA sequencing into clinical diagnostics: Opportunities and challenges. Nat Rev Genet. 2016;17(5):257–271.
    1. Amitay E.L., Cuk K., Niedermaier T., Weigl K., Brenner H. Factors associated with false-positive fecal immunochemical tests in a large German colorectal cancer screening study. Int J Cancer. 2019;144:2419–2427.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera